Table 3.
Risk and burden of SPMN after an index potentially-HPV-associated cancer, by sex and site of index cancer, SEER 2000–2015.
| Index potentially HPV-associated cancer | Observed SPMN | SIR (95 % CI) | EAR per 10000 PYR | |
|---|---|---|---|---|
| Overall | ||||
| All index potentially HPV-associated cancer | 8,203 | 1.73 (1.69, 1.77) | 70.72 | |
| Both men and women | ||||
| Oropharynx | 4,001 | 1.83 (1.78, 1.89) | 109.78 | |
| Anal | 138 | 1.37 (1.15, 1.61) | 45.32 | |
| Men | ||||
| All men index potentially HPV-associated cancer | 3,719 | 1.71 (1.66, 1.77) | 100.16 | |
| Oropharynx | 3,318 | 1.76 (1.70, 1.82) | 103.41 | |
| Anal | 40 | 1.28 (0.91, 1.74) | 39.73 | |
| Penile | 361 | 1.41 (1.27, 1.57) | 76.78 | |
| Women | ||||
| All women index potentially HPV-associated cancer | 4,484 | 1.74 (1.69, 1.79) | 57.10 | |
| Oropharynx | 683 | 2.29 (2.12, 2.47) | 142.42 | |
| Anal | 98 | 1.41 (1.15, 1.72) | 47.76 | |
| Cervical | 2,498 | 1.50 (1.44, 1.56) | 32.56 | |
| Vulvar | 1,045 | 2.29 (2.16, 2.44) | 150.28 | |
| Vaginal | 164 | 1.85 (1.57, 2.15) | 103.70 | |
SPMN = Second primary malignant neoplasm; SEER = Surveillance, Epidemiology, and End Results; SIR = Standardized incidence ratio; EAR = Excess absolute risk per 10000 person-year at risk; CI = Confidence interval.